No sisyphean task: how the FDA can regulate electronic cigarettes.
No sisyphean task: how the FDA can regulate electronic cigarettes.
Yale J Health Policy Law Ethics. 2013;13(2):326-74
Authors: Paradise J
Abstract
The adverse effects of smoking have fostered a natural market for smoking cessation and smoking reduction products. Smokers attempting to quit or reduce consumption have tried everything: "low" or "light" cigarettes; nicotine-infused chewing gum, lozenges, and lollipops; dermal patches; and even hypnosis. The latest craze in the quest to find a safer source of nicotine is the electronic cigarette. Electronic cigarettes (e-cigarettes) have swept the market, reaching a rapidly expanding international consumer base. Boasting nicotine delivery and the tactile feel of a traditional cigarette without the dozens of other chemical constituents that contribute to carcinogenicity, e-cigarettes are often portrayed as less risky, as a smoking reduction or even a complete smoking cessation product, and perhaps most troubling for its appeal to youth, as a flavorful, trendy, and convenient accessory. The sensationalism associated with e-cigarettes has spurred outcry from health and medical professional groups, as well as the Food and Drug Administration (FDA), because of the unknown effects on public health. Inhabiting a realm of products deemed "tobacco products" under recent 2009 legislation, e-cigarettes pose new challenges to FDA regulation because of their novel method of nicotine delivery, various ...
Source: Yale journal of health policy, law, and ethics - Category: Medical Law Tags: Yale J Health Policy Law Ethics Source Type: research
More News: Cancer & Oncology | Chemistry | Dermatology | Food and Drug Administration (FDA) | Health | International Medicine & Public Health | Marketing | Medical Devices | Medical Ethics | Medical Law | Nicotine | Politics | Smokers | Yale